REMARKS/ARGUMENTS

Introductory Remarks

Claims 1, 3-16, 19-26, 29-32, 38-45, 47-52, 54, 56, 58-60, 62-68, 70, 72, and 74-85 are pending in the application. Claims 1, 10, 13, 14, 26, 38, 39, 48, 51, and 56 have been amended. The amendments do not include new matter. Claims 2, 4, 11, 16-18, 27-28, 33-37, 41, 46, 53, 55, 57, 61, 69, 71, and 73 have been canceled. New claims 74-85 have been added herein. New claims 74-85 do not involve new matter. Support for new claims 74-85 can be found throughout the specification, e.g. in Example 6, at p. 43-47 of the 60/439,376 ('376 application), filed 01/10/2003.

Interview Summary

Applicants' attorney Stankovic conducted a telephonic interview with Examiner Medina on April 27, 2009, in order to address outstanding rejections in the present application. In particular, claim amendments to overcome the rejections were discussed. The Examiner is thanked for her consideration in this matter.

Priority

The Office Action contends that the disclosure of the prior-filed provisional patent application, No. 60/439,376 ('376 application), filed 01/10/2003, fails to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. § 112 for one or more claims of the application. In particular, the Office Action contends that the nucleic acid sequences of SEQ ID NOs:4 and 7 and the polypeptide sequences of SEQ ID NOs:5 and 8 are not disclosed in the provisional application. The Office Action therefore contends that "the effective filing date of claims drawn to SEQ ID NO:4, 7, and nucleic acids encoding SEQ ID NO:5 and 8 is 01/12/2004." Applicants respectfully disagree.

1. Disclosure of BAC clone 177O13 in the '376 parent application

First, as indicated in the '376 provisional (parent) patent application, the inventors identified, **disclosed BAC clone 177O13**, and used it for the isolation of the late blight resistance gene of the present invention (e.g., page 39 and SEQ ID NO:1 of the '376 parent application). Therefore, the inventors' disclosure of the BAC clone 177O13 in the '376 parent application, filed 01/10/2003, was before the effective filing date of the Jacobus *et al.* patent application, U.S. 20030221215A1, filed 02/07/2003. It is noted that the Office Action refers to the 20030221215A1 patent application as Allefs *et al.*

Second, the Office Action indicates that "the BAC clone was publicly available as of 05/23/03 which is after the affective filing of Allefs et al." That is not relevant, as the inventors disclosed BAC clone 177O13 in the '376 parent application that was filed on 01/10/2003, which is prior to the effective filing date of the Jacobus *et al.* patent application, U.S. 20030221215A1, and prior to the public disclosure of the BAC clone.

2. <u>Disclosure of SEQ ID NO:4 in the '376 parent application</u>

First, shown in SEQ ID NO:4, at p. 69-71 of the '376 parent application, is a "nucleic acid sequence of disease resistant gene, gene 2 (cloned by PCR). Two exons are highlighted in bold. A single intron is underlined." ('376 application, p. 69; see also Appendix I). When these two identified exons, shown in bold, are joined together, the resulting nucleic acid sequence is 100% identical to the nucleic acid sequence of SEQ ID NO:4 of the instant application. The '376 parent application thus identifies and points out the "two exons" (shown in bold) that need to be joined together and the "single intron" (underlined) that needs to be removed in order to obtain a coding region. Because the specification refers to two exons and a single intron, and graphically describes them (bold and underlined, respectively), one skilled in the art would know to join the two exons together while removing the single intron, in order to obtain the coding region of SEQ ID NO:4. Therefore, the nucleic acid sequence

Application Serial No. 10/755,966 Response dated July 30, 2009 Reply to Office Action of April 30, 2009

of SEQ ID NO:4 of the instant application was fully disclosed in the '376 application.

Second, the entire nucleic acid sequence of SEQ ID NO:4 of the instant application is also shown in the '376 parent application in Example 6, at p. 43-47 of the '376 application (see also Appendix II), in a nucleic acid comparison (alignment). As indicated at p. 43, I. 57-58 of the '376 parent application, the top sequence in the comparison presented in Example 6 refers to the "gene 2 coding region from the resistant homolog". This nucleic acid sequence, disclosed in the '376 parent application, is 100% identical to the nucleic acid sequence of SEQ ID NO:4 of the instant application. In order to advance prosecution of the present application, Applicants request that the Examiner point out the alleged differences in the sequences.

3. Disclosure of SEQ ID NO:5 in the '376 parent application

Shown as SEQ ID NO:5, at p. 71 of the '376 parent application (see also Appendix III), is a "Gene 2 protein sequence (from the resistant homolog)". This amino acid sequence, disclosed in the '376 parent application, is **100% identical to the amino acid sequence of SEQ ID NO:5** of the instant application. Therefore, the amino acid sequence of SEQ ID NO:5 of the instant application was fully disclosed in the '376 parent application. In order to advance prosecution of the present application, Applicants request that the Examiner point out the alleged differences in the sequences.

Accordingly, Applicants respectfully request that the instant application is accorded the correct priority date that corresponds to the date of the filing of the '376 parent provisional patent application, i.e., **January 10, 2003**. Amended claims 1, 10, 13, 14, 26, 38, 39, 48, 51, and 56, and claims dependent from these amended claims, should be accorded the correct priority date that corresponds to the date of the filing of the '376 parent provisional patent application, i.e., **January 10, 2003**.

Claim Rejections - 35 U.S.C. §102

Claims 1,3-16, 19-22, 24-26, 29-32, 38-41, 43-45, and 66 are rejected under 35 U.S.C. 102(e) as allegedly being anticipated by Jacobus *et al.*, U.S. 20030221215A1, published 11/27/2003 (<u>Jacobus</u>). It is noted that the Office Action refers to the 20030221215A1 patent application as Allefs *et al.* <u>Jacobus</u> is published after the priority date of the present patent application (i.e., after 1/10/2003). Therefore, <u>Jacobus</u> does not qualify as a 35 U.S.C. 102(e) reference. Applicants respectfully request that this rejection be withdrawn.

Claim Rejections - 35 U.S.C. §103

It is not clear from the Office Action which claims have been rejected under 35 U.S.C. 103(a), as allegedly being obvious over Jacobus *et al.*, U.S. 20030221215A1, published 11/27/2003 (<u>Jacobus</u>) in view of Staskawics et al., US 6,166,295 (<u>Staskawics</u>). However, because <u>Jacobus</u> is published after the priority date of the present patent application (i.e., after 1/10/2003), <u>Jacobus</u> does not qualify as a 35 U.S.C. 103(a) reference. Applicants respectfully request that this rejection be withdrawn.

SUMMARY

The claims at issue distinguish over the cited references and are in condition for allowance. Applicants respectfully request the Examiner grant early allowance of this application. The Examiner is invited to contact the undersigned attorney for Applicants via telephone at (312) 321-4254 if such communication would expedite this application.

Application Serial No. 10/755,966 Response dated July 30, 2009 Reply to Office Action of April 30, 2009

Respectfully submitted,

/Bratislav Stankovic, Reg. No. 56,999/ Bratislav Stankovic, Ph.D. Registration No. 56,999 Attorney for Applicants

BRINKS HOFER GILSON & LIONE P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200

Appendix I

EDGELO, 6526EHD6

P03170US/WARF-0204

NLRALTSLDISDNVEATSLPEEMFKSLANLKYLKISFFRNLKELPTSLASLNALKSLKFEFCDALESLPE EGVKGLTSLTELSVSNCMMLKCLPEGLQHLTALTTLTITQCPIVFKRCERGIGEDWHKIAHIPYLTLYE

SEQ ID NO:4: Nucleic acid sequence of disease resistant gene, gene 2 (cloned by PCR). Two exons are highlighted in bold. A single intron is underlined.

CGGGATCCTGTCACATAAATTGACACAAAGGGAGTACTTGTTAATGTTGTAATTATTGGCGAACAATAAT GTTGTTGATTATCACTTTCTGAATAAGTGTTGTGTCACTTGGAAAAAAACACCAAATAGAACTATTCATGT TTTTTCTTTAGTATATATAAATATGATCTTTAACTTAATTTCAGCAGACAGTCATGATCTTTAACTTTAA ATGTGCACAAGTAGATTGACAGGCTTGCTAATTGAGTGTCTGTTATAATCAGTATTAAATACTCTCAAGG TANTAGTATATTCCAGACAAATTTTGTGTTACCAAATTAAATATATTTCTAAAACTCTCCTCAAAGTAGT TAATATACTTTTGAGTGTTGTATCATGTTTTTAATATAAAATGTTAAAATTTAGATGAAATTTACTTTCT AGTTAAATTGGTCAAAGTTGAAAGAATTTCAAGTGAAAAAGTTTTTAATAATTTGACTTTTATGCTATAT GGCCTTTATATGATGAAAAAAAAAAAGAAAGTTAGATGACAACAATGTCCAAAAATAATCTTAAAGAAT GATAAATTTTTTTTTTTTTTTTTTTTTACTAATTGCGTATAGAGAAAAGGAAAATGGGGCGGTAATTAC 20 AACAGTACTTCATCTATTCTATTAATTAAATTTTCTATATTAAATTTAATTAAATTTGTGAGGTAATACAAACT TATTAAGAAAAATATTTAAGGACATAATTTAACTCATATTTTTCACTATTGTTTTTTTGTGAAATCATAAA TATAACTTTGTAAATAGTGCAATTTATCTCCTAGAAGCAAATTTCACCAAAGAAAAGGGCAAAGATGGAA AAGAAACTAAATATTCATCTTAAACTTTGAACAATTCAATTATTTTGAACAATGAAAAAATCTCAAAAA TTCAATTAATATGAAATGGAGAGAGTAACTTTATTTTAGAGGCAAAAAATTAGTACTCCATCCGTTCACT TTTATTTGTCATGTTGCGCTTTTCGAAAGTCAATTTGACTAATTTTTAAAGCTAAATTAGATTACACTAA TTCAATATTTTAAACAGAAAAATTAGATATTCAAAAACTATACAAAAAATATTATACATTGCAATTTTTT GCATATCAATATGATAAAAAAATATTGTAAAATATTAGTCAAAATTTTTATAGTTTGACTCTAATCAT GAAAAGTATAATAATTAATAGTGGACGGAGGAAGTATTGTCTTTCCAGATTTGTGGCCATTTTTGGGCCA AGGGCCATTAGCAGTTCTCTTCATTTTCTACTTCTGTCTCATATTAGATGGGCATCTTACTAAAAATATT ATTAATATAGTTTTAAAAGTTTTAAACAAATTTTGAAGAATCAAAATTTCTTTTTGCAAGAGACTTATTA ATATAAACAAAGGATAAAATAATAAAATTTGTCAATTTATTGACGATCACTTAATAATCATATAAAAATAG **ANTATGTTTATCTAATATGAGACGGAGAAAATATATCCTAAAATATTTTTGGACAGATATGTGATATTCT** TTCGATTTTTATTTTATTTATCACTTTTAACCTATCATGTAAAAAGATAATTATTTTTTCATGCTTTA AATTTGTCCGGTCAAACAATGATAAATAAAAACGAATGAAGAGAGTAGAAAACAAAACAAAAGAACAAGT TGACAACTTGAGAGATTAAAAGGGTCCAAAACGCCTTGGATTTTGAGATTCCATATGTGAAAATTTCCATG AAATAATTGAATTTGTATTATTACAAGTCAAACTTCCCATTTCATTCCAACTAGCCATCTTGGTTTCAAA ATTACACATTCATTCACAGATCTAATATTCTTAATAGTGATTTCCACATATGGCTGAAGCTTTCAT tcaagttctgctagacaatctcacttcttcctcaaaggggaacttgtattgcttttccgttttcaagat Gagttccaaaggctttcaagcatgttttctacaattcaagccgtccttgaagatgctcaggagaagcaac 45 TCAACAACAAGCCTCTAGAAAATTGGTTGCAAAAACTCAATGCTGCTACATATGAAGTCGATGACATCTT GGATGAATATAAAACCAAGGCCACAAGATTCTCCCAGTCTGAATATGGCCGTTATCATCCAAAGGTTATC CCTTTCCGTCACAAGGTCGGGAAAAGGATGGACCAAGTGATGAAAAAACTAAAGGCAATTGCTGAGGAAA GAAAGAATTTTCATTTGCACGAAAAAATTGTAGAGAGACAAGCTGTTAGACGGGAAACAGGTACTCATCT CAAATCTGGCAAGCTCAGAATCAAATTATCCACCCCAACTTTTAAATACTCGATATCTTTAGAAATCCAC CGATCCGTTTTGCTTTCTTAACAAAGCAGCTCAGAGAAAAGAGGTTTTCTTCTATTCTGTTTCTCTGTG

- 69 -

TGCTGCACTTGGGTCCTTAATCCCATTAAAAACAGGGCATGTTAATCCCAACGACGGTAGCCTTTCCTGA
CAGCTGACTGTAAATTTTGTCTAACAAAGAAAAAAAAAGATTAGACATGTTTTTCCTTGTCATTGATTAG
GCTGGATTTCTTTCAGAGTGGAACATAGGGGATATATTTGGACCAAAAGTAGAATGGGTATATATTTAAAG

SDRIED. STEPERGS

P03170US/WARF-0204

<u>TATTTCTGATAGAACAGGAGTATATTGTGCGAAAATATCCTCTATTTTCTGTTGTCTCCTAATGAGTTTC</u> AAGAGACAAGAGAAAGATGAGATAGTGAAAAATCCTAATAAACAATGTTAGTGATGCCCAACACCTTTCA GTCCTCCCAATACTTGGTATGGGGGGATTAGGAAAAACGACTCTTGCCCAAATGGTCTTCAATGACCAGA GAGTTACTGAGCATTTCCATTCCAAAATATGGATTTGTGTCTCGGAAGATTTTGATGAGAAGAGGTTAAT **AAAGGCAATTGTAGAATCTATTGAAGGAAGGCCACTACTTGGTGAGATGGACTTGGCTCCACTTCAAAAG AAGCTTCAGGAGTTGCTGAATGGAAAAAGATACTTGCTTTGTCTTAGATGATGTTTTGGAATGAAGATCAAC** AGAAGTGGGCTAATTTAAGAGCAGTCTTGAAGGTTGGAGCAAGTGGTGCTTCTGTTCTAACCACTACTCG tcttgaaaaggttggatcaattatgggaacattgcaaccatatgaactgtcaaacctgtctaagaagat 10 Gaaaggagattgtgaaaaaaagtggtggtgtgcctctagccgaaaactcttggaggtattttgtgctt CAAGAGAGAAGAAGAGCATGGGAACATGTGAGAGACAGTCCGATTTGGAATTTGCCTCAAGATGAAAGT TCTATTCTGCCTGCCCTGAGGCTTAGTTACCATCAACTTCCACTTGATTTGAAACAATGCTTTGCGTATT 15 TCTTTATCAAAAGGAAACATGGAGCTAGAGGATGTGGGCGATGAAGTATGGAAAGAATTATACTTGAGG TCTTTTTTCCAAGAGATTGAAGTTAAAGATGGTAAAACTTATTTCAAGATGCATGATCTCATCCATGATT **ACATATGATGTCCATTGGTTTCGCCGAAGTGGTGTTTTTTTACACTCTTCCCCCCTTGGAAAAGTTTATC** TCGTTAAGAGTGCTTAATCTAGGTGATTCGACATTTAATAAGTTACCATCTTCCATTGGAGATCTAGTAC ATTTAAGATACTTGAACCTGTATGGCAGTGGCATGCGTAGTCTTCCAAAGCAGCTTATGCAAGCTTCAAAA tctgcaaactcttgatctacaatattgcaccaagctttgttgtttgccaaaagaaacaagtaaacttggt **AGTCTCCGAAATCTTTTACTTGATGGTAGCCAGTCATTGACTTGTATGCCCACCAAGGATAGGATCATTGA** cctaaatctctatggctcaattaaaatctcgcatcttgagagagtgaagaatgatatggacgccaaaagaa GCCAATTTATCTGCAAAAGGGAATCTGCATTCTTTAAGCATGAGTTGGAACTTTGGACCACATATAT ATGARTCAGAAGAAGTTAAAGTGCTTGAAGCCTCAAACCACACTCCAATCTGACTTCTTTAAAAATCTA TGGCTTCAGAGGAATCCATCTCCCAGAGTGGATGAATCACTCAGTATTGAAAAATATTGTCTCTATTCTA ATTAGCAACTTCAGAAACTGCTCATGCTTACCACCCTTTGGTGATCTGCCTTGTCTAGAAAGTCTAGAGT TACACTGGGGGTCTGCGGATGTGGAGTATGTTGAAGAAGTGGATATTGATGTTCATTCTGGATTCCCCAC AAGAATAAGGTTTCCATCCTTGAGGAAACTTGATATATGGGACTTTGGTAGTCTGAAAGGATTGCTGAAA AAGGAAGGAGAAGAGCAATTCCCTGTGCTTGAAGAGATGATAATTCACGAGTGCCCTTTTCTGACCCTTT CTTCTAATCTTAGGGCTCTTACTTCCCTCAGAATTTGCTATAATAAAGTAGCTACTTCATTCCCAGAAGA GATGTTCAAAAACCTTGCAAATCTCAAATACTTGACAATCTCTCGGTGCAATAATCTCAAAGAGCTGCCT accagettgetagtetgaatgetttgaaaagtetaaaaattgagtetgeggaetagagagtete CTGAGGAAGGGCTGGAAGGTTATCTTCACTCACAGAGTTATTTGTTGAACACTGTAACATGCTAAAATG 35 tttaccagagggattgcagcacctaacaaccctcacaagtttaaaaattcggggatgtccacaactgatc **TTTAA**GTTATTTGCTATTGTTTCTTTGTTGTGAGTCTTTTTGGTTCCTGCCATTGTGATTGCATGTAAT $\tt TTTTTTCTAGGGTTGTTTGTTTGAGTCTCTCTCTCTCATTGGATGTAATTCTCTTTTGGTAACAAATTA$ ACAATCTATTTGTATTATACGCTTTCAGAATCTATTACTTATTTGTAATTGTTTCTTTGTTAAATTG TGAGTATCTTATTGTATGGAATTTTCTGATTTTATTTTGAAAACAAATCAATAAGATCCATCTGCATTAT ACTCCCTTCGTCTCATTTTATGTGACACTTTTTGGATTTCGAGATTCTTTGATCTTAAATTTTTCATAGA TCTTTTAAACATTTTGAGTTATCAATTATTGTGATTTTAGTATTTTTTATGTAGTTTACAAATACATAAA ATTTATTTTTTTAAAAAAAGAAGATTTCATGCGCAAATTCCCGATCAAACTTAAATTACTAGACTCTCG 45 AAAAATGAAAAGTGTCACATAAATTGAGACAGAGGGAGTACTTGTTAATGTTGTAATTATTGGCGAACAA TAATGTTGGTGATTATCACTTTCTGAATAAATGTTGTGTCACGTGGAAAAAACACCAAATAGAAGTATTC ATGCTTTTTTAGTATATATAAACATGATTTTTAACTTGGTTTCAGCGGATAGTCATGACCTTTAACTCTG **AATGTGCACAAGTAGATACTTGTATAAAATTAAAACAAATTTTATAAAATTATACAATATGACACTGAGAG** TAATTGATACCAATTGCAGTCGTTGCTGCTTTTCGATTCTCTGTCATTCTCTAGGTAATTGATTTTACAG AAAATATCCTTCTACTCATCCTTTTTTGTCTAAAATTACCCTTTCATCCACATTTTTTGCTCACTTATACC AGATAATTAAAATATCTTTAAAAGTACTAGTCATGCCACAATTATAGGGACATAATATATTAATATAAAT

Appendix II

P03170US/WARF-0204

60439376.011003

	351	PLAAKTLCGILCFKREERAWEHVRDSPIWNLPQDESSILPALRLSYHQLP	400
5	351	PLAAKTLGGILCFKREERAWEHVRDSPIWNLPQDESSILPALRLSYHQLP	400
	101	LDLKQCFAYCAYFPKDAKMEKF.KLIST.WMAHGFLLSKGNMELEDVGDEVW	450
	401	LDLKQCFAYCAVFPKDAKMKKEKLISTWMAHGFLLSKGNMELEDVGDEVW	450
10	451	KEL+LRSFFQEIEVKDGKTYFKMHDLIHDLATSLFSANTSSSNIREINKH	500
	451	KELYLRSFFQEIEVKDGKTYFKMHDL1HDLATSLFSANTSSSNIREINKH	500
15	501	SYTHMMSIGFAEVVFFYTLPPLEKFISLRVLNLGDSTFNKLPSSIGDLVH	550
15	501	SYTHMMSIGFAEVVFFYTLPPLEKFISLRVLNLGDSTFNKLPSSIGDLVH	550
	551	LRYLNLYGSGMRSLPKOLCKLONLOTLDLOYCTKLCCLPKETSKLGSLRN	600
20	551	LRYLNLYGSGMRSLPKQLCKLQNLQTLDLQYCTKLCCLPKETSKLGSLRN	600
	601	LLLDGSQSLTCMPPRIGSLTCLKTLGQFVVGRKKGYQLGELGNLNLYGSI	650
25	601	LLLDGSQSLTCMPPRIGSLTCLKTLGQFVVGRKKGYQLGELGNLNLYGSI	650
	651	KISHLERVKNDKUAKEANLSAKGNLHSLSMSWNNFGPHIYESEEVKVLEA	700
	651	KISHLERVKNOMDAKEANLSAKGNLHSLSMSWNNFGPHIYESEEVKVLEA	700
30	701	LKPHSNLTSLKIYGFRGIHLPEWMNHSVLKNIVSILISNFRNCSCLPPFG	750
	701	LKPHSNLTSLKTYGFRGIHLPFWMNHSVLKNJVSILISNFRNCSCLPPFG	750
35	751	DLPCLESLELHWGSADVEYVEEVDIDVHSGFPTRIRFPSLRKLDIWDFGS	800
	751	DLPCLESLEIMWGSADVEYVEEVDIDVHSGFPTRIRFPSLRKLDIWDFGS	800
	801	LKGLLKKEGEEQFPVLEEMITHECPFLTLSSNLRALTSLRICYNKVATSF	850
40	801	LKGLLKKEGEEQFPVLEEMIIHECPFLTLSSNLRALTSLRICYNKVATSF	850
	851	PEEMFKNLANLKYLTISRCNNLKELPTSLASLNALKSLALESLP	894
45	851	PEEMFKNLANLKYLTISRCNNLKELPTSLASLNALKSLKIQLCCALESLP	900
	895	EEGLEGLSSLTELFVEHCNMLKCLPEGLQHLTTLTSLKTRGCPQLIKRCE	944
50	901	EEGLEGLSSLTELFVEHCNMLKCLPEGIQHLTTLTSLKIRGCPQLIKRCE	950
	945	KGJGEDWHKISHIPNVNIYI* 965	
	951	KGIGEDWHKISHIPNVNIYI* 971	

55 Example 6:

The following example shows a nucleic acid comparison between the gene 2 coding regions from a disease resistant and disease susceptible variety. The top sequence is the gene 2 coding region from the resistant homolog. The bottom sequence is the gene 2 coding region

P03170US/WARF-0204

soussys.actions

from the susceptible 177013 homolog. Note that the susceptible homolog contains a C to G point mutation at position 1362 that creates a stop codon in second exon at Tyr454 (residue 454 of 970 total), creating a severely truncated protein, in addition to one mismatch (C to T) at codon 10 which doesn't change the amino acid and one sense mutation (T to C) at codon 22 which alters valine to alanine.

P03170US/WARF-0204

60439376 .011003

	651	TGATGAGAAGAGGTTAATAAAGGCAATTGTAGAATCTATTGAAGGAAG	700
	2245		2196
5	701	CACTACTTGGTGAGATGGACTTGGCTCCACTTCAAAAGAAGCTTCAGGAG	750
	2195	CACTACTTCGTGAGATGGACTTGGCTCCACTTCAAAAGAAGCTTCAGGAG	2146
10	751	TTGCTGAATGGAAAAGATACTTGCTTGTCTTAGATGATGTTTGCAATGA	800
	2145	TTGCTGAATGGAAAAGATACTTGCTTGTCTTAGATGATGTTTTGGAATGA	2096
	801	AGATCAACAGAAGTGGGCTAATTTAAGAGCAGTCTTGAAGGTTGGAGCAA	850
15	2095	AGATCAACAGAAGTCGGCTAATTTAAGAGCAGTCTTGAAGGTTCGAGCAA	2046
	851	GTGGTGCTTCTGTAACCACTACTCGTCTTGAAAAGGTTGGATCAATT	900
20	2045	GTGGTGCTTCTGAACCACTACTCGTCTTGAAAAGGTTGGATCAATT	1996
	901	ATGGGAACATTGCAACCATATGAACTGTCAAACCTGTCTCAAGAAGATTG	950
	1995	ATGGGAACATTGCAACCATATGAACTGTCAAATCTGTCTCAAGAAGATTG	1946
25	951	TTGGTTGTTCATGCAACGTGCATTTGGACACCAAGAAGAAATAAAT	1000
		TTGGTTGTTCATGCAACGTGCATTTGGNCACCAAGAAGAAATNAATC	
30		CAAACCTTGTGGCAATCGGAAAGGAGATTGTGAAAAAAAGTGGTGGTGTG	
		CAAACCTTGTGGCAA'CCGGAAAGGAGATTGTGAAAAAAGTGGTGGTGTG	
25		CCTCTAGCAGCCAAAACTCTTGGAGGTATTTTGTGCTTCAAGAGAGAAGA	
35		CCTCTAGCAGCCAAAACTCTTGGAGGTATTTTGTGCTTCAAGAGAGAACA	
		AAGAGCATGGGAACATGTGAGAGACAGTCCGATTTGGAATTTGCCTCAAG	
40		AAGAGCATGCGAACATGTGAGAGACAGTCCGATTTGGAATTTGCCTCAAG ATGAAAGTTCTATTCTGCCTGCCCTGAGGCTTAGTTACCATCAACTTCCA	
		ATGAAAGTTCTATTCTGCCTGCCCTGAGGCTTAGTTACCATCAACTTCCA	
45		CTTGATTTGAAACAATGCTTTGCGTATTGTGCGGTGTTCCCAAAGGATGC	
		CTTGATTTGAAACAATGCTTTGCGTATTGTGCCGTGTTCCCAAAGGATGC	
		CAAAATGAAAAAAGCTAATCTCTCTCTGGATGGCGCATGGTTTTC	
50			
		TTTTATCAAAAGGAAACATGGAGCTAGAGGATGTGGGCGATGAAGTATGG	
55		TTTTATCAAAAGGAAACATGGAGCTAGAGGATGTGGGCGATGAAGTATGG	
		AAAGAATTATACTTGAGGTCTTTTTTCCAAGAGATTGAAGTTAAAGATGG	
60 .			
		TAAAACTTATTTCAAGATGCATGATCTCCATGATTTGGCAACATCTC	

SCHESESFS COLESCE P03170US/WARF-0204 1495 TAAAACTTATTTCAAGATGCATGATCTCATCCATGATTTGGCAACATCTC 1416 5 1501 AGTTACACACATATGATGTCCATTGGTTTCGCCGAAGTGGTGTTTTTTTA 1550 10 1551 CACTCTTCCCCCCTTGGAAAAGTTTATCTCGTTAAGAGTGCTTAATCTAG 1600 15 1601 GTGATTCGACATTTAATAAGTTACCATCTTCCATTGGAGATCTAGTACAT 1650 1295 GTGATTCGACATTTAATAAGTTACCATCTTCCATTGGAGATCTAGTACAT 1246 1651 TTAAGATACTTGAACCTGTATGGCAGTGGCATGCGTAGTCTTCCAAAGCA 1700 20 1701 GTTATGCAAGCTTCAAAATCTGCAAACTCTTGATCTACAATATTGCACCA 1750 25 1751 AGCTTTGTTTGCCAAAAGAAACAAGTAAACTTGGTAGTCTCCGAAAT 1800 AGCTTTGTTTGCCAAAAGAAACAAGTAAACTTGGTAGTCTCCGAAAT 1096 30 1801 CTTTTACTTGATGGTAGCCAGTCATTGACTTGTATGCCACCAAGGATAGG 1850 35 1851 ATCATTGACATGCCTTAAGACTCTAGGTCAATTTGTTGGTAGGAAGA 1900 1901 AAGGTTATCAACTTGGTGAACTAGGAAACCTAAATCTCTATGGCTCAATT 1950 40 45 2001 CAATTTATCTGCAAAAGGGAATCTGCATTCTTTAAGCATGAGTTGGAATA 2050 CAATTTATCTGCAAAAGGGAATCTGCATTCTTTAAGCATGAGTTGGAATA 846 50 2051 ACTTTGGACCACATATATATGAATCAGAAGAACTTAAAGTGCTTGAAGCC 2100 55 2151 AATCCATCTCCCAGAGTGGATGAATCACTCAGTATTGAAAAATATTGTCT 2200 60

P03170US/WARF-0204

60439376 .D11003

		CTATTCTAATTAGCAACTTCAGAAACTGCTCATGCTTACCACCCTTTGGT	
5	695	CTATTCTAATTAGCAACTTCAGAAACTGCTCATGCTTACCACCCTTTGGT	646
	2251	GATCTGCCTTGTCTAGAAAGTCTAGAGTTACACTGGGGGTCTGCGGATGT	2300
	. 645	GATCTGCCTTGTCTAGAAAGTCTAGAGTTACACTGGGGGTCTGCGGATGT	596
10	2301	GGAGTATGTTGAAGAAGTGGATATTGATGTTCATTCTGGATTCCCCACAA	2350
10	595		546
	2351	GAATAAGGTTTCCATCCTTGAGGAAACTTGATATATGGGACTTTGGTAGT	2400
15	545	GAATAAGGTTTCCATCCTTGAGGAAACTTGATATATGGGACTTTGGTAGT	496
	2401	CTGAAAGGATTGCTGAAAAACGAAGGAGAAGAGCAATTCCCTGTGCTTGA	2450
20	495	CTGAAAGGATTGCTGAAAAAGGAAGGAGAAGAGCAATTCCCTGTGCTTGA	446
20	2451	AGAGATGATAATTCACGAGTCCCCTTTCTGACCCTTTCTCTAATCTTA	2500
	445	AGAGATGATAATTCACGAGTGCCCTTTCTGACCCTTTCTTATCTTA	396
25	2501	GGGCTCTTACTTCCCTCAGAATTTGCTATAATAAAGTAGCTACTTCATTC	2550
	395	GGGCTCTTACTTCCCTCAGAATTTGCTATAAAAGTAGCTACTTCATTC	346
	2551	CCAGAAGAGATGTTCAAAAACCTTGCAAATCTCAAATACTTGACAATCTC	2600
30	345	[296
	2601	TCGGTGCAATAATCTCAAAGAGCTGCCTACCAGCTTGGCTAGTCTGAATG	2650
35	295	TCGGTGCAATAATCTCAAAGAGCTGCCTACCAGCCTGGCTAGTCTGAATG	246
	2651	CTTTGAAAAGTCTAAAAATTCAATTGTGTTGCGCACTAGAGAGTCTCCCT	2700
40	245	CTTTGAAAAGTCTAGCACTAGAGAGTCTCCCT	214
40	2701	GAGGAAGGCTGGAAGGTTATCTTCACTCACAGAGTTATTTGTTGAACA	2750
	213	GAGGAAGGGCTGGAAGGTTATCTTCACTCACAGAGTTATTTGTTGAACA	164
45	2751	CTGTAACATGCTAAAATGTTTACUAGAGGGATTGCAGCACCTAACAACCC	2800
	163	CTGTAACATGUTGAAATGTTTACCAGAGGGATTGCAGCACCTAACAACCC	114
50	2801	TCACAAGTTTAAAAATTCGGGGATGTCCACAACTGATCAAGCGGTGTGAG	2850
	113	TCACAAGTTTAAAAATTCGGGGATGTCCACAACTGATCAAGCGGTGTGAG	64
55	2851	AAGGGAATAGGAGAAGACTGGCACAAAATTTCTCACATTCCTAATGTGAA	2900
	63		1.4
	2901	TATATATATTTAA 2913	
60	. 13		
00			

- 47 -

Appendix III

EDGLLG, 65EPEPG

P03170US/WARF-0204

SEQ ID NO:5: Gene 2 protein sequence (from the resistant homolog)

GCTTTGAGTTCTTTTCTTTATGGATCCCG

- 20 MAEAFIQVLLDNLTSFLKGELVLLFGFQDEFQRLSSMFSTIQAVLEDAQEKQLNNKPLENWLQKLNAATY
 EVDDILDEYKTKATRFSQSEYGRYHPKVIPFRHKVGKRMDQVMKKLKAIAEERKNFHLHEKIVERQAVRR
 ETGSVLTEPQQYGRDKEKDEIVKLLINNVSDAQHLSVLPILGMGGLGKTTLAQMVFNOQRVTEHFHSKIW
 ICVSEDFDEKRLIKAIVESIEGRPLLGEMDLAPLQKKLQELLNGKRYLLVLDDVWNEDQQKWANLRAVLK
 VGASGASVLTTTRLEKVGSIMGTLQPYELSNLSQEDCWLLFMQRAFGHQEEINPNLVAIGKEIVKKSGGV
 PLAAKTLGGILCFKREERAWEHVRDSPIWNLPQDESSILPALRLSYHQLPLDLKQCFAYCAVFPKDAKMK
 KEKLISLWMAHGFLLSKGNMELEDVGDEVWKELYLRSFFQEIEVKDGKTYFKMHDLIHDLATSIFSANTS
 SSNIREINKHSYTHMMSIGFAEVVFFYTLPPLEKFISLRVLNLGDSTFNKLPSSIGDLVHLRYLNLYGSG
 MRSLPKQLCKLQNLQTLDLQYCTKLCCLPKETSKLGSLRNLLLDGSQSLTCMPPRIGSLTCLKTLGQFVV
 GRKKGYQLGELGNLNLYGSIKISHLERVKNDMDAKEANLSAKGNLHSLSMSWNNFGPHIYESEEVKVLEA
 10 LKPHSNLTSLKIYGFRGIHLPEWMNHSVLKNIVSILISNFRNCSCLPPFGDLPCLESLELHWGSADVEYV
 EEVDIDVHSGFPTRIRFFSLRKLDIWDFGSLKGLLKKEGEEQFPVLEEMIIHECPFITLSSNLRALTSLR
 ICYNKVATSFPEEMFKNLANLKYLTISRCNNLKELPTSLASLNALKSLKIQLCCALESLPEEGLEGLSSL
 TELFVEHCNMLKCLPEGLQHLTTLTSLKIRGCPQLIKRCEKGIGEDWHKISHIPNVNIYI
- 35 SEQ ID NO:6: Nucleic acid sequence of disease resistant genc, gene 3 (from the resistant homolog)
- ATGGCTGAAGCTTTCCTTCAAGTTCTGCTAGATAATCTCACTTTTTTCATCCAAGGGGAACTTGGATTGG TTTTTGGTTTCGAGAAGGAGTTTAAAAAACTTTCAAGTATGTTTTCAATGATCCAAGCTGTGCTAGAAGA ${\tt TGCTCAAGAGAACTGAAGTACAAGGCAATAAAGAACTGGTTACAGAAACTCAATGTTGCTGCATAT$ GAAGTTGATGACATCTTGGATGACTGTAAAACTGAGGCCAGGATTCAAGCAGGCTGTATTGGGGCCTT ATCATCCACGGACCATCACTTTCTGTTACAAGGTGGGAAAAAGAATGAAGAAATGATGGAAAAACTAGA TGCAATTGCAGAGGAACGGAGGAATTTTCATTTAGATGAAAGGATTATAGAGAGACAAGCTGCTAGACGG CAAACAGGTTTTGTTTTAACTGAGCCAAAAGTTTATGGAAGGGAAAAAGAGGAGGATGAGATAGTGAAAA TCTTGATAAACAATGTTAGTTATTCCGAAGAAGTTCCAGTACTCCCAATACTTGGTATGGGGGGACTAGG AAAGACGACTCTAGCCCAAATGGTCTTCAATGATCAAAGAATTACTGAGCATTTCAATCTAAAGATATGG GTTTGTGTCTCAGATGATTTTGATGAGAAGAGGTTGATTAAGGCAATTGTAGAATCTATTGAAGGAAAGT CACTGGGTGACATGGACTTGGCTCCCCTCCAGAAAAAGCTTCAGGAGTTGTTGAATGGAAAAAGATACTT **TCTTGTTTTGGATGTTTGGAATGAAGATCAAGAAAAGTGGGATAATCTTAGAGCAGTATTGAAGATT** GGAGCTAGTGGTGCTTCAATTCTAATTACTACTCGTCTTGAAAAAATTGGATCAATTATGGGAACTTTGC CCAAACCGAAACAAGTCCTAAACTTATGGAAATCGGAAAGGAGATTGTGAAGAAATGTGGGGGTGTGCCT CTAGCAGCCAAAACTCTTGGAGGCCTTTTACGCTTCAAGAGGGAAGAAAGTGAATGGGAACATGTGAGAG TCTTCCACTTGATTTGAGACAATGTTTTGCATATTGCGCAGTATTCCCAAAGGACACCAAAATAGAAAAG GAATATCTCATCGCTCTCTGGATGGCACACAGTTTTCTTTTATCAAAAGGAAACATGGAGCTAGAGGATG